Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of CT0596 CAR-T in relapsed/refractory multiple myeloma
CTR20263131Phase 2Active
- Sponsor
- UKZ Biopharma
- Start
- Aug 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of CT0596 in multiple myeloma (MM), sponsored by UKZ Biopharma. Started Aug 2026; status: active.
02
Drugs
CT0596
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20263131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263131.